News Takeda's Ninlaro fails phase 3 amyloidosis trial Takeda is discontinuing a trial of its drug Ninlaro in systemic light-chain AL amyloidosis after it did not meet the first of two primary endpoints.
News Takeda’s myeloma drug Ninlaro approved in Europe Takeda has gained European Union approval of its multiple myeloma drug Ninlaro for second line use – joining a wave of new treatments for the incurable condition.
News Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends